TORONTO, Sept. 9, 2011 /CNW/ - Amorfix Life Sciences, a product
development company focused on diagnostics and therapeutics for
misfolded protein diseases, today announced that it has appointed Ms.
Meryl J. Chertoff, Director of The Aspen Institute's Justice and
Society Program and Adjunct Professor of Law at Georgetown Law, to its
Board of Directors.
Ms. Chertoff's legal career includes senior roles at various high
profile government offices and agencies. She is a leader in
educational programs regarding the US Federal and State courts. She
served in the Office of Legislative Affairs at the Federal Emergency
Management Agency (FEMA), participating in the agency's transition into
the Department of Homeland Security in 2003. Ms. Chertoff has also been
a legislative relations professional, Director of New Jersey's
Washington, D.C. Office under two governors, and legislative counsel to
the Chair of the New Jersey State Assembly Appropriations Committee.
She served on the Board of the Anti-Defamation League of New Jersey,
and chaired its civil rights committee. She was Director of the Sandra
Day O'Connor Project on the State of the Judiciary at Georgetown Law,
studying and educating the public about federal and state courts. At
Georgetown Law, she also developed educational programs for visiting
judges and other government officials from overseas. Ms. Chertoff is a
magna cum laude graduate of Harvard-Radcliffe College and earned her
J.D. from Harvard Law School.
In addition to work at the Aspen Institute and Georgetown Law, Ms.
Chertoff is a member of the O'Connor Judicial Selection Initiative
Advisory Committee at the Institute for the Advancement of the American
Legal System at the University of Denver; a member of the Washington
Area Advisory Committee of Common Sense Media; and a Trustee of the
Meridian International Center in Washington, DC, where she chairs the
Arts Advisory Committee.
Philippe Couillard, Chairman of the Amorfix Board of Directors,
commented, "We are very pleased to welcome Ms. Chertoff to the
Company's Board. Ms. Chertoff's legal expertise, committee experience
and other impressive qualifications will be a great addition to our
Board of Directors."
Amorfix Life Sciences Ltd. (TSX: AMF) is a product development company
developing therapeutic products and diagnostic devices targeting
misfolded protein diseases including Alzheimer's Disease (AD), cancers,
and ALS. Amorfix utilizes its computational discovery platform,
ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the
molecular surface of misfolded proteins. Amorfix's lead programs
include therapeutics and companion diagnostics for cancers, antibodies
and vaccines to DSEs in ALS and AD diagnostic tests. In addition,
Amorfix's proprietary Epitope Protection™ technology enables it to
specifically identify very low levels of misfolded proteins in a
biological sample. The Company's diagnostic programs include an
ultrasensitive method for the detection of aggregated beta-Amyloid in
brain tissue, CSF and blood from animal models of AD, months prior to
observable amyloid formation, and development of a human screening test
for AD. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by the Company in its
public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise.
SOURCE Amorfix Life Sciences Ltd.
For further information:
| Dr. Robert Gundel |
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
| || || || || || || || || Janet Clennett |
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899